(Q36980721)

17 August 2017

1 reference

title

Management of hepatitis B in liver transplant recipients (English)

1 reference

17 August 2017

1 reference

2

Norah A Terrault

1 reference

17 August 2017

Carla S Coffin

1

1 reference

17 August 2017

1 November 2007

1 reference

Journal of Viral Hepatitis

17 August 2017

1 reference

17 August 2017

14 Suppl 1

1 reference

17 August 2017

37-44

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Improving outcomes for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00916.X

10.1111/J.1365-2893.2007.00916.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17958641